An equal number of cells from selected ASCI-R clones (n = 5), each harboring a unique BCR::ABL1 mutation (B73—A337V, B91—K294E, C22—L510P, C113—D276G, and D62—A337T) were used to establish a cell-line derived xenograft (CDX) model of polyclonal CML resistant to asciminib (Supplementary Methods). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.